As investors continue to jump on small sparks of hope in the pandemic pipeline Sanofi and Regeneron inject a dose of reality.
On the corporate front Astellas continued to buy, while Qiagen decided that it was not, after all, up for sale.
Pharming picks up Novartis’s late-stage PI3K inhibitor and plans to launch it for an ultra-rare disease. How will the competition respond?
A damning report by the US pricing watchdog Icer could bode ill for the uptake of Shire’s big hereditary angioedema hope.
A US complete response letter leaves Ruconest at the mercy of rivals like Shire.
Shire's big pipeline hope, lanadelumab, should get approved soon – but will sales live up to expectations?